Multidisciplinary care use in neurodegenerative complex diseases: The example of progressive supranuclear palsy and advanced Parkinson's disease in real-life

Fabbri, Margherita; Ledda, Claudia; Schirinzi, Tommaso; Artusi, Carlo Alberto; Avallone, Anna Rosa; Zenuni, Henri; De Micco, Rosa; Aloisio, Simone; Cani, Ilaria; Malaguti, Maria Chiara; Di Biasio, Francesca; Calandra-Buonaura, Giovanna; Stefani, Alessandro; Lopiano, Leonardo; Barone, Paolo; Picillo, Marina; Serio, Marina; Zibetti, Maurizio; Bissacco, Jacopo; Satolli, Sara; Sambati, Luisa; Bacchin, Ruggero; Longo, Chiara; Marchese, Roberta; Panetta, Salvatore; Magistrelli, Luca; Contaldi, Elena; Moschella, Vincenzo; Altavista, Maria Concetta; Costanzo, Matteo; Fabbrini, Giovanni; Olivola, Enrica; Modugno, Nicola; Cincotta, Massimo; Piccininni, Maristella; Capecci, Marianna; Baldini, Nicolò; Ciammola, Andrea; Ticozzi, Nicola; Raffaella, Di Giacopo; De Togni, Laura; Sala, Francesca; Nicoletti, Alessandra; Cicero, Edoardo; Ceravolo, Roberto; Del Prete, Eleonora

doi:10.1016/j.parkreldis.2024.107047

Parkinsonism & Related Disorders

2024

DOI: 10.1016/j.parkreldis.2024.107047

|View full text |Cite

Multidisciplinary care use in neurodegenerative complex diseases: The example of progressive supranuclear palsy and advanced Parkinson's disease in real-life

Margherita Fabbri,

Claudia Ledda,

Tommaso Schirinzi

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

2025

Publication Types

Select...

Article4

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Immunometabolic Signature and Tauopathy Markers in Blood Cells of Progressive Supranuclear Palsy

Rosina,

Veltri,

Nesci

et al. 2024

Movement Disorders

View full text Add to dashboard Cite

BackgroundPeripheral immune cells critically contribute to the clinical‐pathological progression of neurodegenerative diseases and also represent a reliable frame for translational applications. However, data on progressive supranuclear palsy (PSP) are almost scarce in this regard.ObjectiveOur goal is to provide a broad biological characterization of peripheral immune cells in a selected PSP cohort.MethodsSeventy‐one PSP patients scored on the PSP Rating Scale (PSPRS), and 59 controls were enrolled. The blood cell count was collected, together with the neutrophil‐to‐lymphocyte ratio (NLR) calculation. In a subgroup of patients and controls, the peripheral blood mononuclear cells (PBMCs) were analyzed by the mitochondrial bioenergetic performance and the western blot assay of the nuclear factor erythroid 2‐related factor (NRF2)/heme oxygenase 1 (HO‐1) pathway and the total tau (t‐tau) and phosphorylated tau (p‐tau) proteins. Case–control comparison and correlation analyses were performed.ResultsPSP patients had a NLR higher than controls, with increased circulating neutrophils. The leukocyte metabolism was also globally increased and the NRF2/HO‐1 pathway activated in patients. P‐tau, but not t‐tau, significantly accumulated in PSP PBMCs and inversely correlated with the PSPRS.ConclusionsPSP displays a systemic inflammatory shift of the peripheral immunity, which may justify a metabolic reprogramming of the blood leukocytes. Consistently, the NRF2/HO‐1 pathway, a master regulator of inflammatory and metabolic response, was activated. PBMCs also engulf tau proteins, especially p‐tau, in a way inverse to the disease severity, allowing for a peripheral tracking of tauopathy in patients. Immunometabolic targets may, therefore, gain relevance to PSP in biomarker or therapeutic purposes. © 2024 International Parkinson and Movement Disorder Society.

show abstract

Immunometabolic Signature and Tauopathy Markers in Blood Cells of Progressive Supranuclear Palsy

Rosina,

Veltri,

Nesci

et al. 2024

Movement Disorders

View full text Add to dashboard Cite

show abstract

Reply to: “A Short Progressive Supranuclear Palsy Quality of Life Scale: Data from the PSP‐NET”

Jensen,

Bebermeier,

Stiel

et al. 2024

Movement Disorders

View full text Add to dashboard Cite

A Short Progressive Supranuclear Palsy Quality of Life Scale: Data from the PSP‐NET

Cappiello,

Barone,

Picillo

2024

Movement Disorders

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Multidisciplinary care use in neurodegenerative complex diseases: The example of progressive supranuclear palsy and advanced Parkinson's disease in real-life

Cited by 4 publications

References 27 publications

Immunometabolic Signature and Tauopathy Markers in Blood Cells of Progressive Supranuclear Palsy

Immunometabolic Signature and Tauopathy Markers in Blood Cells of Progressive Supranuclear Palsy

Reply to: “A Short Progressive Supranuclear Palsy Quality of Life Scale: Data from the PSP‐NET”

A Short Progressive Supranuclear Palsy Quality of Life Scale: Data from the PSP‐NET

Contact Info

Product

Resources

About